Previsioni di mercato delle malattie cardiometaboliche in Europa fino al 2028 – Impatto del COVID-19 e analisi regionale per tipologia (malattie cardiovascolari (CVD), diabete di tipo 2, ipertensione e obesità), trattamento (ACE inibitori, diuretici, glucofagi e altri), dosaggio (compresse e iniezione), via di somministrazione (orale ed endovenosa), utenti finali (ospedali, cliniche e strutture di assistenza domiciliare) e canale di distribuzione (farmacia ospedaliera, farmacia al dettaglio e farmacia online)
Introduzione al mercato
La malattia cardiometabolica è caratterizzata da un gruppo di anomalie e sintomi che aumentano il rischio che gli individui sviluppino malattie cardiovascolari. Ipertensione, obesità, resistenza all’insulina, dislipidemia, basso profilo di colesterolo (LDL) e tolleranza al glucosio sono alcuni dei sintomi. Gli individui affetti da sindrome cardiometabolica sono soggetti a numerose altre malattie potenzialmente letali come il diabete di tipo 2, ictus, malattia coronarica (CAD), malattie cardiovascolari (CVD) e molte altre.
Inoltre, si prevede che la crescente prevalenza delle malattie cardiometaboliche rafforzerà la crescita del mercato durante il periodo di previsione. Tuttavia, la sottodiagnosi delle malattie cardiovascolari nei paesi a basso e medio reddito (LMIC) limita la crescita del mercato europeo delle malattie cardiometaboliche.
In Europa, la pandemia di COVID-19 ha avuto conseguenze significative implicazioni sulla cura cardiovascolare dei pazienti. Coloro che vivono con malattie cardiovascolari preesistenti hanno un rischio maggiore di deterioramento della salute e di morte nel contrarre il COVID-19. I servizi di prevenzione, diagnosi e trattamento delle malattie cardiovascolari sono stati gravemente interrotti dalla pandemia di COVID-19. Secondo MedTech Europe, circa il 95% di tutti i decessi per COVID-19 aveva almeno una condizione di base, tra cui le malattie cardiovascolari sono la principale comorbilità (65%). Inoltre, è diminuito di circa il 50% il numero di persone che si recano negli ospedali e in altre strutture sanitarie con sintomi di infarto o ictus, creando un significativo arretrato di pazienti con gravi condizioni di salute. Inoltre, la riduzione delle presenze al pronto soccorso per patologie cardiache rispetto all’anno precedente è scesa tra il 31% e l’88% dopo il lockdown nel Regno Unito, con un impatto negativo sulla crescita del mercato. La pandemia ha avuto un impatto significativo sul mercato nel breve termine; tuttavia, il mercato crescerà a un ritmo moderato nel periodo di previsione.
Panoramica e dinamiche del mercato
Si prevede che il mercato europeo delle malattie cardiometaboliche raggiungerà i 33.963,6 milioni di dollari entro il 2028 rispetto ai 26.717,5 milioni di dollari del 2021; si prevede che crescerà a un CAGR del 3,5% dal 2021 al 2028. Uno strumento di rischio integrato (IRT), creato da Genomics plc, sarà utilizzato per stimare il rischio di ciascun paziente di sviluppare una malattia cardiovascolare entro i prossimi 10 anni. La società ha affermato che se l’IRT fosse applicato a tutte le persone di età compresa tra i 40 e i 60 anni nel Regno Unito, potrebbe identificare più di 650.000 persone ad alto rischio di malattie cardiovascolari, non rilevate dallo screening attuale. Oltre a questo, i recenti progressi nell’Internet delle cose (IoT), nel cloud computing e nell’intelligenza artificiale (AI) hanno migliorato significativamente il sistema sanitario convenzionale. Nell’agosto 2021, gli scienziati della South Ural State University (SUSU) hanno sviluppato un modello per una diagnosi più efficace di malattie cardiovascolari e diabete, utilizzando l’intelligenza artificiale e l’IoT. Inoltre, l’integrazione dell’intelligenza artificiale offre ulteriori opportunità redditizie per la crescita del mercato delle malattie cardiometaboliche e si prevede che continuerà a sostenere questo mercato nel periodo di previsione. Nel giugno 2021, l\'ACC e GE Healthcare hanno collaborato attraverso il supporto e la partecipazione all\'Applied Health Innovation Consortium (AHIC) dell\'ACC per creare una tabella di marcia per l\'intelligenza artificiale e la tecnologia digitale in cardiologia e sviluppare nuove strategie per migliorare i risultati sanitari.
Segmenti chiave del mercato
In termini di tipologia, il segmento delle malattie cardiovascolari ha rappresentato per la quota maggiore del mercato europeo delle malattie cardiometaboliche nel 2020. In termini di trattamento, il segmento degli ACE inibitori ha rappresentato la quota maggiore del mercato europeo delle malattie cardiometaboliche nel 2020. In termini di dosaggio, il segmento delle compresse ha rappresentato la quota maggiore di mercato europeo delle malattie cardiometaboliche nel 2020. In termini di via di somministrazione, il segmento orale ha rappresentato la quota maggiore del mercato europeo delle malattie cardiometaboliche nel 2020. In termini di utente finale, il segmento ospedaliero ha rappresentato la quota maggiore del mercato europeo delle malattie cardiometaboliche. mercato delle malattie nel 2020. Inoltre, in base al canale di distribuzione, il segmento delle farmacie ospedaliere ha detenuto la quota di mercato maggiore nel 2020.
Principali fonti e società elencate
Alcune delle principali fonti primarie e secondarie citate per la preparazione di questo rapporto sul mercato delle malattie cardiometaboliche in Europa sono società siti web, relazioni annuali, relazioni finanziarie, documenti governativi nazionali e database statistici, tra gli altri. Le principali aziende elencate nel rapporto sono Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc. e Kowa Company, Ltd.
Rapporto sui motivi per acquistare
- Comprendere il panorama del mercato europeo delle malattie cardiometaboliche e identificare i segmenti di mercato che potrebbero garantire un forte rendimento
- Comprendere il panorama del mercato in continua evoluzione e rimanere all\'avanguardia nella concorrenza
- Pianificare in modo efficiente fusioni, acquisizioni e accordi di partnership nel mercato europeo delle malattie cardiometaboliche identificando i segmenti con le vendite probabili più promettenti
- Prendere decisioni aziendali consapevoli partendo da un\'analisi perspicace e completa dell\'andamento del mercato dei vari segmenti
- Ottenere previsioni sulle entrate del mercato europeo delle malattie cardiometaboliche basate sul mercato su vari segmenti per il periodo 2021-2028
SEGMENTAZIONE DEL MERCATO DELLE MALATTIE CARDIOMETABOLICHE IN EUROPA
Per Tipo
- Malattia cardiovascolare ( CVD)
- Diabete di tipo 2
- Ipertensione
- Obesità
Per trattamento
- ACE inibitori
- Diuretici
- Glucofago
- Altri
Per dosaggio
- Compressa
- Iniezione
Per via di somministrazione
- Orale
- Per via endovenosa
Da parte degli utenti finali
- Ospedale
- Clinica
- Impostazioni per l\'assistenza domiciliare
Per canale di distribuzione
- Farmacia ospedaliera
- Farmacia al dettaglio
- Farmacia online
Per paese
- Europa
- Germania
- Regno Unito
- Francia
- Spagna
- Italia
- Resto d\'Europa
Società menzionate
- Eli Lilly and Company.
- Bayer AG
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd .
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Europe Cardiometabolic Diseases market – By Country
2. Europe Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Europe Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Europe Cardiometabolic Diseases Market – Regional Analysis
6.1 Europe Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Europe Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Europe Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Europe Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Europe Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Europe Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Europe Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Europe Cardiometabolic Diseases Market – Geographic Analysis
13.1 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028
13.1.1 Overview
13.1.2 Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.3 Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.4 Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.5 Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.6 Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.7 Europe: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.8 Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.9 Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
13.1.9.1 Germany Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.9.1.1 Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.10 Germany: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.11 Germany: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.12 Germany: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.13 Germany: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.14 Germany: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.15 Germany: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UK Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.15.1.1 UK; Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.16 UK: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.17 UK: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.18 UK: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.19 UK: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.20 UK: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.21 UK: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.21.1 France Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.21.1.1 France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.22 France: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.23 France: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.24 France: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.25 France: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.26 France: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.27 France: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Italy Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.27.1.1 Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.28 Italy: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.29 Italy: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.30 Italy: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.31 Italy: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.32 Italy: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.33 Italy: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.33.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.33.1.1 Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.34 Spain: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.35 Spain: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.36 Spain: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.37 Spain: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.38 Spain: Cardiometabolic Diseases Market, by End User, Revenue and Forecast to 2028 (USD Million)
13.1.39 Spain: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
13.1.39.1 Rest of Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.39.1.1 Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
13.1.40 Rest of Europe: Cardiometabolic Diseases Market Revenue, by Type, Revenue and Forecast to 2028 (USD Million)
13.1.41 Rest of Europe: Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
13.1.42 Rest of Europe: Cardiometabolic Diseases Market, by Dosage, Revenue and Forecast to 2028 (USD Million)
13.1.43 Rest of Europe: Cardiometabolic Diseases Market, by Route of Administration, Revenue and Forecast to 2028 (USD Million)
13.1.44 Rest of Europe: Cardiometabolic Diseases Market, by End User Revenue and Forecast to 2028 (USD Million)
13.1.45 Rest of Europe: Cardiometabolic Diseases Market, Distribution Channel, Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
14.1 Europe: Impact Assessment of COVID-19 Pandemic
15. Europe Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Novartis AG
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Boehringer Ingelheim International GmbH
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Novo Nordisk A/S
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 AstraZeneca
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Alnylam Pharmaceuticals, Inc.
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Kowa Company, Ltd.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 3. Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 5. Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 6. Europe Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 7. Germany Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Germany Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 9. Germany Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Germany Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 11. Germany Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 12. Germany Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 13. UK Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UK Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 15. UK Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UK Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 17. UK Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 18. UK Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 19. France Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. France Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 21. France Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. France Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 23. France Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 24. France Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 25. Italy Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Italy Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 27. Italy Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Italy Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 29. Italy Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 30. Italy Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 31. Spain Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 32. Spain Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 33. Spain Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 34. Spain Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 35. Spain Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 36. Spain Cardiometabolic Diseases Market, by Distribution Channel, – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Europe Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 38. Rest of Europe Cardiometabolic Diseases Market, by Treatment– Revenue and Forecast to 2028 (USD Million)
Table 39. Rest of Europe Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 40. Rest of Europe Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million
Table 41. Rest of Europe Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million
Table 42. Rest of Europe Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 43. Organic Developments in the Cardiometabolic Diseases Market
Table 44. Inorganic Developments in the Cardiometabolic Diseases Market
Table 45. Glossary of Terms, Europe Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Europe Cardiometabolic Diseases Market Segmentation
Figure 2. Europe Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Europe Cardiometabolic Diseases Market
Figure 4. Europe Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Europe Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Europe PEST Analysis
Figure 7. Europe Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Europe Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Europe: Cardiometabolic Diseases Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 34. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 35. Europe Cardiometabolic Diseases Market Revenue and Forecasts to 2028, By Country (%)
Figure 36. Germany: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 37. UK: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 38. France: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 39. Italy: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 40. Spain Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 41. Rest of Europe: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 42. Impact of COVID-19 Pandemic on Europe Cardiometabolic Diseases Market
Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Kowa Company, Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.